Purpose: Mitomycin C (MMC) plus standard 5-fluorouracil (FU) infusion in weeks 1 and 5 often contributes to radiotherapy interruptions and possibly less-than-ideal outcomes in anal cancer.
INTRODUCTION
Chemoradiation has revolutionized the treatment of squamous cell carcinoma of the anus. It has evolved from a neoadjuvant role 1,2 to becoming the definitive treatment. A series of landmark clinical trials that addressed various treatment factors, including: the issue of adding chemotherapy to radiation, 3, 4 the specific role of mitomycin C (MMC), 5 the place for neoadjuvant and adjuvant chemotherapy, 6, 7 the roles of MMC and cisplatin, 6, 7 and selection of patients for elective inguinal radiation 8 have led to the current standard treatment of radiation with infusion 5-fluorouracil (FU) in weeks 1 and 5, and bolus dose MMC. This regimen provides superior tumor control, survival rates and functional outcomes. Improved radiotherapy technique with intensity-modulated radiation therapy (IMRT) has further refined an already excellent treatment with reduced acute toxicity. 9 Chemoradiation, however, often leads to significant acute perineal skin toxicity, and a treatment interruption is frequently necessary. 7, [9] [10] [11] In a clinical trial evaluating radiation dose escala-
Treatment protocol
The treatment consisted of a single bolus dose of MMC followed by FU in continuous ambulatory infusion administered with a radical course of pelvic radiotherapy.
MMC was dosed at 10 mg/m 2 and administered as a bolus dose on the first day of radiotherapy. The FU was administered at 300 mg/m 2 /day via ambulatory infusion pump for 96 hours a week for the whole course of radiotherapy, beginning on the first day of radiotherapy and stopping immediately after the last radiotherapy treatment.
All gross disease, both anal and involved nodes, was treated to a total dose of 54 Gy, 1.8 Gy/fraction, 5 days per week, over 6 weeks.
Prophylactic radiotherapy of 36 Gy was given to the inguinal regions for T2-T4 and for patients with involved nodes.
Radiotherapy was delivered in three phases: pelvic-inguinal field, pelvic field, and boost field. Pelvic fields were planned to cover the primary tumor and lateral pelvic nodes. The superior border was at the inferior sacroiliac joints, or 5 cm proximal to the primary tumor, whichever was more proximal. The inferior border was 3 cm below the primary tumor. The lateral borders were 1 cm lateral to the pelvic brim.
The posterior border was a minimum of 1 cm behind the anterior bony sacral margin, and the anterior border was 3 cm anterior to the primary tumor. The boost field was planned to treat the tumor and clinically involved nodes with a 2 cm margin.
For T1 N0 M0, the pelvic field was treated to 45 Gy in 25 fractions, in 1.8 Gy per fraction over a 5-week period, with a 3-field technique. This was followed immediately by the boost field for another 9 Gy in 5 fractions over 5 days. No attempts were made to cover the inguinal regions.
For T2-4 N0-1 M0, the pelvic-inguinal field was treated to 36 Gy in 20 fractions, in 1.8 Gy per fraction over 4 weeks, with anterior and posterior opposing fields. The pelvic field received an additional 9 Gy. A further 9 Gy was delivered to the boost field. In total, gross tumor was treated to a dose of 54 Gy and inguinal regions a dose of 36 Gy. For T1-4 N2-3 M0, the radiotherapy field and dose were identical to that for T2-4 N0-1 M0 except the involved inguinal region was treated with electron field to a total dose of 54 Gy. The uninvolved inguinal region was treated to 36 Gy only.
Treatment interruption
Radiotherapy interruption was allowed after grade 3 or grade 4 toxicity. Radiotherapy was recommenced once toxicity grade had decreased to 2 or lower. Chemotherapy was interrupted in the event of any radiotherapy interruption, and recommenced once radiotherapy resumed.
Chemotherapy was interrupted for grade 3-4 nonhematologic toxicity that was clearly due to chemotherapy alone and resumed with a dose reduction at the discretion of the investigators. 
Patient assessments
Pretreatment assessments included clinical evaluation (history, physical examination, WHO performance status assessment, and toxicity assessment), full blood examination (FBE), renal and liver function tests, tumor biopsy, chest X-ray and CT abdomen and pelvis.
Assessments during treatment included weekly FBE blood tests and toxicity assessments. At 2 weeks after completion of chemoradiation, FBE, renal and liver function tests were taken, and toxicity and performance status were assessed. The patient was assessed for clinical response at 2 months after completion of treatment, and 2 monthly until complete response was observed. Thereafter, the patient was assessed every 3 months for toxicity and disease status.
Statistical considerations
The accrual target of this study was 50 patients. Accrual was expected to be completed in 60 months. With this sample size, the overall response rate (complete and partial responses) would be estimated with a maximum standard error of 7%.
Patient demographics, pretreatment disease characteristics and treatment received were summarized using descriptive statistics, including the median and range for data measured on a continuous scale and counts and percentages for categorical data. Percentages were rounded up to the nearest whole number.
Acute and late radiation morbidity were assessed according to the appropriate EORTC/RTOG scoring criteria. 15 All toxicities were summarized by grade and grade 3 or 4 toxicities were specifically listed together with time of onset (from start of protocol treatment).
The objective response rate was calculated as the number of complete or partial responders divided by the number of patients who commenced treatment, expressed as a percentage. The 95% confidence interval for the objective response rate was calculated using the Blyth-Still-Casella method.
The treatment interruption rate was calculated as the number of patients having an RT treatment interruption due to toxicity as a percentage of all patients who commenced treatment. The 95% confidence interval for the interruption rate was calculated using the Blyth-Still-Casella method.
Disease-free survival was measured from the date of commencement of RT until the date of first failure, where failure was persistent disease or recurrence, or death from any cause. For patients with persistent disease, disease-free survival was measured from the commencement to conclusion of RT. Colostomy-free survival was measured from the date of commencement of RT until the date of colostomy or death, whichever occurred first. Overall survival was measured from the date of commencement of RT until the date of death from any cause.
The Kaplan-Meier method was used to estimate disease-free survival, colostomy-free survival and overall survival for all patients.
Times were censored at the study close-out date for patients who were still being followed up without having experienced the relevant event by the close-out date, or the date of last contact for patients lost to follow-up without a prior event. For disease-free survival, the location of first failure was summarized and a competing risks analysis was used to estimate cumulative incidence rates for each type of failure.
Quality control
Data were collected on study specific case record forms designed by the study statistician. The study co-ordinator entered the data into a database created by the trial center, using Microsoft Access software. Data queries were generated by the study co-ordinator in liaison with the study statistician. All queries were rectified at the time the statistical report was completed.
TA B L E 1 Patient characteristics

RESULTS
Fifty patients were recruited between December 1997 and May 2003.
Of these, 36 were female (72%). The median patient age at time of registration was 60.5 years, and the range of ages of the participants was 35-84. The patient characteristics are listed in Table 1 .
Protocol compliance
Forty-seven patients (94%) received 54 Gy to the tumor. Prophylactic inguinal nodal irradiation was delivered to 33 patients (66%). Fifteen patients with involved inguinal nodes were treated to the tumor dose (54 Gy in 87%). Seven patients (14%) had reductions in FU dose.
median duration of chemoradiation was 39 days (37-105 days).
Thirteen patients (26%) had a break in the delivery of their planned chemoradiation: 12 due to severe toxicity, and 1 due to treatment overlapping public holidays. Of those with treatment breaks due to toxicity, 10 breaks were due to grade 3 or 4 perineal skin toxicity, 1 was due to hospitalization for investigation of fever and diarrhea, and 1 was for nausea, diarrhea and abdominal pain.
Treatment-related toxicity
Acute radiation toxicities are listed in Table 2 . Pelvic skin and lower GI toxicities were most common. Pelvic skin toxicity was the commonest severe acute toxicity experienced (G3 62%, G4 2%). Lower GI tract toxicities were mainly grade 1 and 2 (G1 21%, G2 48%, G3 4%).
Late radiation toxicities are listed in Table 3 . All patients had differing degrees of skin changes. Gastrointestinal toxicity was also common, with most cases being grade 1 (62%) or 2 (16%). No cases of grade 3 or 4 toxicity were noted.
In correlating between acute and late toxicity, a total of 32 patients developed Grade 3 or higher acute skin toxicity. Of those, 10 patients developed G3 or higher late skin toxicity (31%). Conversely, in 14 patients who developed G3 or higher late skin toxicity, 4 patients (29%) did not experience severe acute skin toxicity. Ten patients had treatment interruptions due to severe acute skin toxicity. Half of these (five patients) subsequently developed G3 or G4 late skin toxicity.
Survivals and failures
The median potential follow-up was estimated at 7.3 years.
The estimated disease-free survival rate at 5 years was 74% (95% CI, 60-84%) and at 9 years was 61% (95% CI, 46-74%; see Figure 1 ).
The estimated overall survival rate at 5 years was 84% (95% CI, 71-92%) and at 9 years was 67% (95% CI, 50-81%; see Figure 2 ).
Cumulative incidence by location of first failure at 5 and 9 years were 16% (S.E. 5%) and 18% (S.E. 6%) for local failure, and 4% (S.E. 3%) and 4% (S.E. 3%) for distant failure, respectively. Of eight patients who failed locally, two patients (25%) had treatment breaks.
Eight patients (16%) were known to have had a colostomy, with a further eleven patients dying without having received a colostomy. The estimated colostomy-free survival rate at 5 years was 70% (95% CI, 56-81%) and at 9 years was 57% (95% CI, 40-72%).
DISCUSSION
In this study, chemoradiation with protracted infusion FU and bolus dose MMC had similar tumour control and survival rates compared to randomized studies. The 5-year disease-free survival of 74% (95% CI, 60-84%) compared favorably with RTOG 98-11 (67.8%) and ACT II (69%). The estimated overall survival rate at 5 years of 84% (95% CI, 71-92%) was comparable to RTOG 98-11 (78.3%) and ACT II (79%).
The colostomy-free survival rate was also comparable: 70% (95% CI, We did not observe reduction of severe perineal skin toxicity with this regimen. Grade 3-4 toxicity rates were similar to other studies where high dose infusion FU was given in week 1 and 5 together with MMC. In the RTOG 98-11 trial, grade 3-4 toxicity occurred in 58.8%, with skin toxicity the most common event. In the ACT II trial, grade 3-4 toxicity occurred in 48% of patients in the FU/MMC group during chemoradiation. We reviewed individual data and correlated grade ≥3 acute and late skin toxicity. Thirty-one percent of patients with severe acute toxicity developed severe late toxicity. Of those who had severe late skin toxicity, 29% did not have severe acute toxicity. In addition, toxicityrelated treatment breaks did not eliminate severe late toxicity, as 50% of this group subsequently developed late toxicity. Our data suggest that acute skin toxicity is not a reliable predictor for severe late skin toxicity.
TA B L E 2 Acute radiotherapy toxicities
TA B L E 3 Late radiotherapy toxicities
IMRT was not used in this study. All patients were treated with 3D conformal radiotherapy. Improvement of radiotherapy techniques with IMRT will enable delivery of radiation to a highly conformal target volume. Minimizing radiation dose to the small intestine will reduce gastrointestinal toxicity. 17 Reducing the dose to bone marrow will decrease hematotoxicity. Optimising dose homogeneity will further reduce toxicity and improve tumor control. However, as the primary anal cancer will always require high dose radiation of 50 Gy or more, it will be difficult to substantially reduce skin toxicity even with these highly conformal techniques. The policy of interruption according to patient-reported toxicity will be a useful guide for timing treatment breaks.
The backbone of chemoradiation for anal cancer has not changed for many years. 50-55 Gy in combination with chemotherapy is the standard treatment for nearly all patients. While this is an effective treatment with a high success rate, this one-size-fits-all approach clearly needs to be refined. The ongoing PLATO (personalizing anal cancer radiotherapy dose) comprises three separate trials which aim to optimize radiotherapy dose for low-, intermediate-and high-risk anal cancer. 18 This trial may provide guidance to the optimal radiation dose for different stages of disease.
It is also possible that radiation doses can be adjusted according to other risk factors, such as p16 status. Carcinomas of the anal canal are strongly associated with human papillomavirus (HPV). Expression of p16 is used as a surrogate marker of HPV infection, and p16 positivity is an independent prognostic factor for overall survival and disease-free survival. 19 It also appears to be an important factor in local control. 20 Other opportunities for de-escalation of radiation dose exist. 21 Further study is needed to improve an already excellent treatment.
Although randomized data are not available to support its use, capecitabine has been widely accepted in chemoradiation for anal cancer. It is welcomed by consumers for its convenience, and by health authorities for its lower treatment cost. It is comforting to learn that two large-scale retrospective studies have shown its safety and efficacy. 22, 23 The current PLATO randomized study will provide data to confirm this observation. As it is likely that future improvement will come in small increments, the importance of conducting randomized trials for this rare cancer cannot be overstated. The strength of this study is that it is a prospective study, and all patients were treated in a single institute by the lower gastrointestinal radiation oncology team. The compliance rates in terms of registration of patients, treatment delivery, and data collection were high. No patients were lost to follow up. Prospective collection of acute and late toxicity allowed acute and late toxicity analysis for each patient.
Although the study sample was relatively small, a high acute perineal skin toxicity rate allowed credible assessment of possible consequential effect, as well as assessment of treatment breaks initiated by patient-reported toxicity.
As far as we are aware, correlation of acute with late reactions in individual cases has not been reported in anal cancer. However, the small sample size would not allow assessment of the relative efficacy and safety of this regimen compared to the traditional approach of chemoradiation with bolus MMC and week 1 and 5 infusion FU. Our regimen does not seem to be inferior to this standard, but confirmation is necessary.
CONCLUSION
It is feasible to deliver chemoradiation with bolus MMC and protracted infusion FU for anal cancer. Efficacy and toxicity of this regimen seem similar to conventional chemoradiation with FU/MMC.
